No Abstract BioWorld International CorrespondentPARIS - Pharnext, a start-up that is developing new treatments for severe neurological diseases, raised €2.5 million (US$3.68 million) in seed funding from the French venture capital firm Truffle Capital.

LONDON - Investors in Proximagen Neurosciences plc resisted the lure of offers to buy the company and settled, for now, on a licensing agreement with Boehringer Ingelheim. (BioWorld International)